

Groups Recover Together Clinical Model & Outcomes

2023

recover together


THE OVERDOSE EPIDEMIC

is one of the greatest public health challenges of our time, and it's worsening rapidly:

28% YoY increase
50% of all overdose deaths involve polysubstance
70% involve opioids
80% of those in need do not access care



1999



PATTERNS OF OVER- AND UNDER-UTILIZATION WITHIN SUD TREATMENT LEAD TO LOW-VALUE CARE & HIGH COST

Expensive, low-value services are **OVERUTILIZED**:



46% receive ED services (avg 2 days per person in tx)



49% receive inpatient or residential services (avg 10 days per person in tx)



74% get no outpatient follow up

While high-value, effective modalities remain UNDERUTILIZED:





THE GROUPS RECOVERY SYSTEM IS BUILT TO BREAK THE CYCLE



Diagnoses

Modalities

Our flexible, weekly model ensures that members receive the services and support they need FROM DAY ONE THROUGH ONGOING RECOVERY






OUR UNIQUE MODEL DELIVERS CLINICAL OUTCOMES 2-4X THE INDUSTRY STANDARD.

6 Month Retention is the key benchmark for clinical efficacy in our industry

% of patients engaged in treatment 6 months after intake



12/31/20 to 6/30/21; Sample size: 796 enrolled, 598 retained

6

Source: Groups KPIs; Proposed Medicaid HEDIS benchmark via NCQA; Mattick, Richard P., et al. "Mark Olfson, "Buprenorphine Treatment By Primary Care Providers, Psychiatrists, Addiction Specialists, And Others," Health Affairs, June 1, 2020, https://www.healthaffairs.org/doi/abs/10.1377/hlthaff.2019.01622?journalCode=hlthaff.

Attendance and abstinence are leading indicators of retention and predictors of long-term recovery

% scheduled group therapy sessions attended and % urine drug screens negative for illicit opioids, alcohol and stimulants

Weekly Attendance at Group Therapy



Sample size: 269,768 scheduled sessions; 232,447 attended sessions


Abstinence from illicit substances




GROUPS' TREATMENT REDUCES TOTAL COST OF CARE COMPARED TO OTHER FORMS OF SUD CARE, AS WELL AS NON-ENGAGEMENT

MONTHLY TOTAL COST OF CARE (PMPM)

- Claims cost analyzed for 1,597 MCO members receiving treatment from Groups and 2,923 members with an OUD diagnosis (Dates of service 4/2017-4/2022
- Total cost of care inclusive of physical, behavioral, and prescription spend







Groups' Reduction in Spend : \$443 PMPM

Groups vs Not in Any Treatment




Groups' Reduction in Spend : \$88 PMPM




GROUPS IS PARTICULARLY IMPACTFUL FOR HIGH-COST/ HIGH-RISK MEDICAID BENEFICIARIES

MONTHLY TOTAL COST OF CARE (PMPM) for Members with Previous Conditions/Events




Groups has substantially improved relative performance in cases of more severe opioid use disorder. In particular, the percent savings for overdose patients are very large, suggesting that this group derives above-average benefit from Groups treatment and should be considered a target. Large-scale claims analysis shows:

LONGER RETENTION IN TREATMENT YIELDS BIGGER REDUCTIONS IN TOTAL COST OF CARE FOR SUD PATIENTS






OUR MEMBERS HAVE A VARIETY OF SDOH NEEDS WHICH WE EFFECTIVELY ADDRESS THROUGH CARE NAVIGATION



BUNDLED STRUCTURE SIMPLIFIES RECONCILIATION WHILE DELIVERING REDUCTIONS IN TOTAL COST OF CARE

TOTAL COST OF CARE (PMPM) FOR "CURRENT TREATMENT" COMPARED TO ENGAGED MEMBERS

Illustrative example based on previous plan analysis



BENEFITS OF BUNDLED CONTRACT STRUCTURE

- Groups' bundled rate includes existing OP care and holistic services not covered by fee schedule (peer support, education, SDOH, case management), as well as a 50% shared savings on 33-42% total cost of care reduction
- Rate tied to clinical outcomes (i.e 6-month retention) avoiding complicated reconciliation on shared savings. Retention in treatment at 6 months is correlated to 33-42% total cost of care reduction
- Rate only paid for members meeting minimum service requirement (otherwise services delivered at no cost to plan)
- The plan is protected by a 75% fee reduction should Groups not meet clinical outcomes



GROUPS' MODEL DIRECTLY SUPPORTS HEDIS PERFORMANCE

KEY HEDIS METRICS GROUPS CAN SUPPORT

METRIC	DESCRIPTION	INDUSTRY AVERAGE*	GROUPS' COHORT PERFORMANCE	HOW WE IMPACT PERFORMANCE
Pharmacotherapy for OUD (POD)	Percent of new OUD pharmacotherapy events with Rx for 180+ days	28%-38%	54%	 Clinical model highlights weekly prescribing in conjunction with group
Initiation and engagement of treatment (IET, Engagement)	Percent of members who initiate treatment and had 2+ services within 34 days	8%-28%	72%	 Retention in treatment and engagement exceeds benchmarks
Follow up after hospitalization/intensive care/ED (FUA/FUI/FUH)	Percent of ED/IP hospitalizations receiving a follow up outpatient appointment	13%-40%	55%-79%	 Rapid access to care (within 48 hours) Weekly scheduling ensures compliance with 30- day measures
Adult access to preventative services (AAP)	Members receiving preventative health care services	N/A	N/A	 Care navigators work closely with each member on total health outcomes



Appendix

recover together


OUR MODEL DELIVERS INDUSTRY-LEADING REDUCTIONS IN TOTAL SPEND, PHYSICAL HEALTH SPEND, AND BEHAVIORAL HEALTH SPEND, INCLUSIVE OF OUR RATE

Analysis time period: January 2020 – July 2022

Relative to the "matched cohort", GRT spend on OUD members was:

- 33% less overall (\$2.9M over 12 months)
- 46% less for behavioral health (\$1.74M over 12 months)
- 23% less for physical health (\$1.2M over 12 months)








WE HAVE PROVEN OUR ABILITY TO SCALE WITH QUALITY

OPEN



NATIONAL PRESENCE... 125+ Offices in 17 States

...AND EXPANDING Opening 75+ offices next year



QUALITY & OUTCOMES 50k+ commercial, Medicaid, Medicare, and uninsured members served; national CARF accreditation



Connectivity with primary care, ED, corrections and payers drives population-level impact

BUILT FOR VALUE 95% of payer contracts are bundled; proven ability to take upside/ downside risk



WE DEPLOY THE FULL SPECTRUM OF EVIDENCE-BASED MODALITIES REQUIRED TO EFFECTIVELY MANAGE SUD

		OPIOIDS	ALCOHOL	STIMULANT	NICOTINE	PSYCH
	Medication management	\checkmark	\checkmark	N/A	\checkmark	\checkmark
	Laboratory screenings	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
	Toxicology testing	\checkmark	\checkmark	\checkmark	\checkmark	N/A
QA	Health screenings	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
	Collaborative care	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
	Counseling	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
BEHAVIORAL MODALITIES	Individualized treatment planning	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
	Peer support	\checkmark	\checkmark	\checkmark	\checkmark	N/A
<i>K</i>	Community Reinforcement	\checkmark	\checkmark	\checkmark	\checkmark	N/A
	Measurement based care	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
	Behavioral incentives/ Contingency Mgmt.	\checkmark	\checkmark	\checkmark	\checkmark	N/A
SOCIAL MODALITIES	SDOH screenings	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
R	High-touch support and referrals	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark
8–8	Care coordination	\checkmark	\checkmark	\checkmark	\checkmark	\checkmark




THE GROUPS MODEL IS UNIQUELY EFFECTIVE FOR HIGH RISK & HIGH COST POPULATIONS WHO MANY PROVIDERS REFUSE TO SERVE

PREGNANCY

4.1% of Groups Members are pregnant; these members stabilize in treatment during pregnancy and remain stable after

Member data from 1/1/19-6/30/21





ATTENDANCE % of patients engaged in treatment 6 months after intake compared to





CRIMINAL JUSTICE INVOLVED

Groups delivers transitional care & community services for those leaving incarceration; Groups reduces recidivism & fatal overdose upon release by 70%



87% attended the first scheduled appointment

<u>ŤŤŤŤŤŤŤŤŤ</u>Í

97% remain in the community (i.e. have not been reincarcerated)



88% were admitted by Groups within 48 hours of release




94% are employed






OUR DIGITAL PRODUCT INCREASES OUR REACH, ENHANCES OUR OUTCOMES, AND DELIVERS A DELIGHTFUL EXPERIENCE TO EXISTING AND NEW MEMBERS





GROUPS' HYBRID MODEL DELIVERS CONSISTENT OUTCOMES WHETHER MEMBERS ENGAGE VIRTUALLY OR IN-PERSON



Timeline: 456 Days



GROUPS' HOLISTIC IMPACT ON SUBSTANCE USE BEYOND OPIOIDS IS IMMEDIATE AND DURABLE TO 18 MONTHS

Our model is grounded in the belief that addiction is both a medical and a social condition; by addressing the disease holistically, we're able to achieve holistic outcomes

	Month of Treatment								
	Intake	1	2	3	4	5	6	12	18
Illicit Opioids Pos %	28%	7%	4%	3%	3%	2%	2%	1%	0%
UDS Results	7,635	30,650	19,488	19,376	14,312	12,514	12,260	5,435	2,224
AMP Pos %	18%	8%	6%	5%	5%	4%	4%	3%	2%
BUP Pos %	75%	97%	98%	98%	98%	98%	98%	98%	96%
BZO Pos %	10%	4%	3%	3%	2%	2%	2%	2%	1%
COC Pos %	7%	4%	2%	2%	2%	2%	2%	1%	0%
FEN Pos %	19%	10%	6%	5%	5%	4%	3%	2%	1%
MET Pos %	16%	6%	4%	3%	3%	3%	2%	1%	1%
MTD Pos %	3%	1%	0%	0%	0%	0%	0%	0%	0%
OPI Pos %	16%	3%	2%	2%	2%	1%	1%	0%	0%
OXY Pos %	6%	1%	1%	1%	1%	1%	1%	0%	0%
THC Pos %	37%	32%	32%	33%	33%	33%	33%	33%	31%
Stim Pos %	25%	12%	8%	7%	7%	6%	6%	4%	3%
Illicit Pos %	45%	18%	13%	11%	11%	9%	9%	7%	5%
Non Opioid Illicit Pos %	31%	14%	11%	9%	9%	8%	7%	6%	4%

Month of Treatment

MEMBERS WHO REMAIN ENROLLED AT 6-MONTHS ARE LIKELY TO MAINTAIN LONG-TERM SOBRIETY

